Factor X deficiency is a rare coagulation disorder that can be hereditary or acquired. The typology and severity of the associated bleeding symptoms are highly heterogeneous, adding to the difficulties of diagnosis and management. Evidence-based guidelines and reviews on factor X deficiency are generally limited to publications covering a range of rare bleeding disorders. Here we provide a comprehensive review of the literature on factor X deficiency, focusing on the hereditary form, and discuss the evolution in disease management and the evidence associated with available treatment options. Current recommendations advise clinicians to use single-factor replacement therapy for hereditary disease rather than multifactor therapies such as fresh frozen plasma, cryoprecipitate, and prothrombin complex concentrates. Consensus in treatment guidelines is still urgently needed to ensure optimal management of patients with factor X deficiency across the spectrum of disease severity.

Diagnosis, therapeutic advances, and key recommendations for the management of factor X deficiency / F. Peyvandi, G. Auerswald, S.K. Austin, R. Liesner, K. Kavakli, M.T. Alvarez Roman, C.M. Millar. - In: BLOOD REVIEWS. - ISSN 0268-960X. - 50(2021 Nov), pp. 100833.1-100833.10. [10.1016/j.blre.2021.100833]

Diagnosis, therapeutic advances, and key recommendations for the management of factor X deficiency

F. Peyvandi
Primo
;
2021

Abstract

Factor X deficiency is a rare coagulation disorder that can be hereditary or acquired. The typology and severity of the associated bleeding symptoms are highly heterogeneous, adding to the difficulties of diagnosis and management. Evidence-based guidelines and reviews on factor X deficiency are generally limited to publications covering a range of rare bleeding disorders. Here we provide a comprehensive review of the literature on factor X deficiency, focusing on the hereditary form, and discuss the evolution in disease management and the evidence associated with available treatment options. Current recommendations advise clinicians to use single-factor replacement therapy for hereditary disease rather than multifactor therapies such as fresh frozen plasma, cryoprecipitate, and prothrombin complex concentrates. Consensus in treatment guidelines is still urgently needed to ensure optimal management of patients with factor X deficiency across the spectrum of disease severity.
Diagnosis; Factor X deficiency; Plasma-derived factor X concentrate; Prothrombin complex concentrates; Rare bleeding disorders; Treatment
Settore MED/09 - Medicina Interna
nov-2021
Article (author)
File in questo prodotto:
File Dimensione Formato  
1-s2.0-S0268960X21000394-main.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 679.08 kB
Formato Adobe PDF
679.08 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/904148
Citazioni
  • ???jsp.display-item.citation.pmc??? 6
  • Scopus 26
  • ???jsp.display-item.citation.isi??? 22
  • OpenAlex ND
social impact